Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Levis

Showing results (41-50 of 133) with videos related to

Pageof 14
Sort By:
Blood|June 15, 2007
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemiasJudith E Karp, Rebecca M Ricklis, Kumudha Balakrishnan, et al.
Blood Advances|March 5, 2021
Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinibCheryl A C Peretz, Lisa H F McGary, Tanya Kumar, et al.
Leukemia Research|June 24, 2023
Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophiliaTania Jain, Alisha D Ware, William Brian Dalton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk featuresJudith E Karp, B Douglas Smith, Ivana Gojo, et al.
Cancer Research|September 20, 2017
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other MalignanciesJ Kyle Bruner, Hayley S Ma, Li Li, et al.
Experimental Hematology & Oncology|August 1, 2024
1q jumping translocation as a biomarker in myeloid malignancy: frequently mutated genes associated with bad prognosis and low survivalEitan Halper-Stromberg, Victoria Stinnett, Laura Morsberger, et al.
Blood|June 8, 2018
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in <i>FLT3</i>-ITD-mutated, relapsed or refractory AMLJorge E Cortes, Martin S Tallman, Gary J Schiller, et al.
Blood Advances|April 13, 2018
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with <i>FLT3</i>-ITD mutationsMark J Levis, Alexander E Perl, Jessica K Altman, et al.
Blood|November 23, 2016
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AMLSteven Knapper, Nigel Russell, Amanda Gilkes, et al.
Blood Advances|March 27, 2020
The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicingW Brian Dalton, Eric Helmenstine, Lisa Pieterse, et al.
Pageof 14

Showing results (41-50 of 133) with videos related to

Sort By:
Pageof 14
Blood|June 15, 2007
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemiasJudith E Karp, Rebecca M Ricklis, Kumudha Balakrishnan, et al.
Blood Advances|March 5, 2021
Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinibCheryl A C Peretz, Lisa H F McGary, Tanya Kumar, et al.
Leukemia Research|June 24, 2023
Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophiliaTania Jain, Alisha D Ware, William Brian Dalton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk featuresJudith E Karp, B Douglas Smith, Ivana Gojo, et al.
Cancer Research|September 20, 2017
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other MalignanciesJ Kyle Bruner, Hayley S Ma, Li Li, et al.
Experimental Hematology & Oncology|August 1, 2024
1q jumping translocation as a biomarker in myeloid malignancy: frequently mutated genes associated with bad prognosis and low survivalEitan Halper-Stromberg, Victoria Stinnett, Laura Morsberger, et al.
Blood|June 8, 2018
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in <i>FLT3</i>-ITD-mutated, relapsed or refractory AMLJorge E Cortes, Martin S Tallman, Gary J Schiller, et al.
Blood Advances|April 13, 2018
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with <i>FLT3</i>-ITD mutationsMark J Levis, Alexander E Perl, Jessica K Altman, et al.
Blood|November 23, 2016
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AMLSteven Knapper, Nigel Russell, Amanda Gilkes, et al.
Blood Advances|March 27, 2020
The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicingW Brian Dalton, Eric Helmenstine, Lisa Pieterse, et al.
Pageof 14